Abstract:Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer. The 5-year survival rate is low, only at 39% for localized disease and 3% for distant disease. Serum CA19-9 level has been used as a diagnostic marker for PDAC but the lower sensitivity in early-stage patients and false positive in non-cancerous conditions limit its clinical utility for PDAC detection. Therefore, an effective detection approach is still needed to improve disease outcome. Recent technological advances in the detection of tumor-originating circulating free DNA (cfDNA) provide new opportunities for diagnosis and surveillance of PDAC. In this study, we performed parallel genetic and epigenetic profiling of cfDNA from Chinese PDAC patients, as well as healthy individuals, by targeted ultra-deep sequencing and targeted bisulfite sequencing. For methylome profiling, we first identified PDAC-specific differentially methylated regions (DMRs) in tissues and then employed machine learning approach to select the most informative features. Diagnostic models were built to distinguish PDAC patients from healthy individuals. Models were also built to predict prognosis in PDAC patients. A total of 1173 DMRs were identified from comparison of 32 pairs of PDAC cancer vs. para-cancerous tissues. For the diagnostic model, the training cohort consisted of 119 PDAC patients (median age of 63) and 113 age-matched healthy individuals (median age of 60). A random forest classifier achieved an AUC of 0.95±0.04 with 10-fold cross-validation using a panel of 14 DMR markers. Meanwhile, cfDNA mutation profiling achieved a sensitivity of 48.8% and a specificity of 98.2% in the training cohort, providing an inferior diagnostic performance compared to the methylation-based assay. Further analyses were performed in an independent validation cohort, including PDAC patients (n=51) as well as healthy control (n=96). The cfDNA methylation model achieved a sensitivity of 86.3%, and a specificity of 97.6%; stage I sensitivity was 81.0%. On the other hand, the diagnostic model achieved a sensitivity of 44.4% and a specificity of 98.0% based on mutation profile, and serum CA19-9 level alone achieved a sensitivity of 80.4% in this cohort. Next, we tried to further improve the performance of PDAC diagnostic model by combining methylation profile, mutation profile and serum CA19-9 level. A sensitivity of 95.7% was achieved in model combining genetic and epigenetic markers and further increased to 97.8% by including serum CA19-9 level. For the prognostic model, we also found that dual-omics-based prognostic score incorporating both mutation burden and methylation-based prognostic score (MPS) was an independent prognostic predictor. In conclusion, our results suggest that cancer-derived epigenetic abnormalities provide promising biomarkers for the detection of PDAC. We could further improve performance of the PDAC classifier by incorporating mutation profile and serum CA19-9 level. Moreover, integration of genetic and epigenetic alterations may improve prognosis stratification and guide decision making in pretreatment setting.

The Diagnostic Value of Automated Quantitative DNA Cytometry for Pancreatic Malignancy

Comparison of Double Contrast-Enhanced Ultrasound and MDCT for Assessing Vascular Involvement of Pancreatic Adenocarcinoma: Preliminary Results Correlated with Surgical Findings

Diagnostic value of imaging examinations in pancreatic cystic neoplasm

Preliminary application of double contrast-enhanced ultrasonography to assess the peripancreatic vascular invasion of pancreatic carcinoma

The diagnostic accuracy of TCT plus HPV-DNA for cervical cancer: systematic review and meta-analysis

Value of Helical Computed Tomography and Color Doppler Flowing Imaging in Assessing the Resectability of Pancreatic Cancer

Value of the P53 Protein for Diagnosing Cancer in Pancreatic Cells Obtained by Endoscopic Pancreatic Duct Brushing

Celluar DNA Quantitative Analysis in Cytology for Clincal Application in Diagnosis

An Assessment of Chromosomal Alterations Detected by Fluorescence in Situ Hybridisation in Pancreatobiliary Tract Malignancy.

Artificial Intelligence Algorithm-Based Computerized Tomography Image Features Combined with Serum Tumor Markers for Diagnosis of Pancreatic Cancer

The diagnostic value of combining preoperative serum CA19-9, ALBI score, and 18 F-FDG PET/CT imaging in preoperative resectability of pancreatic cancer

Application value of combined detection of exfoliative cytology,DNA heteroploid analysis and serum tumor marker in malignant pleural/ascitic fluid

The additive diagnostic value of cytology in fine needle biopsy of pancreatic adenocarcinoma: A tertiary center experience

Homogenizer for continuous homogenization.

Combined Exosomal GPC1, CD82, and Serum CA19-9 as Multiplex Targets: A Specific, Sensitive, and Reproducible Detection Panel for the Diagnosis of Pancreatic Cancer

Integrated epigenetic biomarkers in circulating cell-free DNA as a robust classifier for pancreatic cancer

The diagnostic performance of contrast-enhanced ultrasound versus contrast-enhanced computed tomography for pancreatic carcinoma: a systematic review and meta-analysis

P-212 The genetic and epigenetic abnormalities of plasma cfDNA as liquid biopsy biomarkers for diagnosis and prognosis stratification of pancreatic ductal adenocarcinoma

Value of contrast-enhanced ultrasound combined with percutaneous ultrasound-guided fine-needle aspiration in the diagnosis of solid pancreatic lesions

Investigating the Value of Dual-Layer Spectral Detector CT in Distinguishing Resectable Pancreatic Ductal Adenocarcinoma from Mass-Forming Chronic Pancreatitis

The effect of the concentrations of carbon dioxide and oxygen in the storage atmosphere upon the sprouting of potatoes at 10°C